Pediatric Academic Societies' 2011Annual Meeting Denver 2011.4.30～5.3

Treatment strategy for jaundiced newborns with high serum unbound bilirubin levels: auditory outcomes in a prospective clinical trial in Japan.
Yokota T, Morioka I, Matsuo K, Fujioka K, Morikawa S, Miwa A, Shibata A, Kodera T, Morisawa T, Yokoyama N, Yonetani M, Matsuo M.

Dose thrombocytopenia increase the risk for patent ductus arteriosus in Japanese premature newborns?
Fujioka K, Morioka I, Matsuo K, Yokota T, Hashimoto F, Morikawa S, Miwa A, Shibata A, Yokoyama N, Matsuo M.

Alport syndrome associated with hemophilia A-molecular mechanism of phenotypic divergence between siblings.
Hashimura Y, Nozu K, Otsubo H, Hashimoto S, Ishimori S, Morisada N, Kaito H, Iijima K, Matsuo M.

Recurrent exercise-induced acute renal failure and PRES with severe renal hypouricemia by compound-heterozygous *SLC2A9* mutation.
Shima Y, Nozu K, Togawa H, Kaito H, Iijima K, Matsuo M, Nakanishi K, Yoshikawa N.

Efficacy of maintenace therapy with mycophenolate mofetil after rituximab for steroid-dependent nephrotic syndrome.
Ito S, Udagawa T, Ogura M, Sako M, Kamei K, Iijima K.

the 1st European Conference of Microbiology and Immunology Budapest 2011.5.12-14

Fetal therapy with use of hyperimmunoglobulin in symptomatic congenital cytomegalovirus infection.
Tanimura K, Sonoyama A, Morizane M, Morioka I, Matsuo M, Yamada H.

Cytomegalovirus infection screening in mothers and neonates.
Sonoyama A, Tanimura K, Morizane M, Morioka I, Tairaku S, Ohashi M, Funakoshi T, Koyano S, Inoue N, Minematsu T, Yamada H.

The 11th Asian Congress of Pediatric Nephrology Fukuoka 2011.6.2～4

Rituximab for refractory nephrotic syndrome.
Iijima K.

National survey of rituximab treatment for childhood idiopathic nephrotic syndrome.
Ito S, Kamei K, Udagawa T, Ogura M, Fujimaru T, Ishikawa T, Sato M, Fujinaga S, Iijima K.

NPHS1 gene analysis in Japanese patients with congenital nephrotic syndrome.
Mukaiyama H, Nakanishi K, Togawa H, Hama T, Shima Y, Iijima K, Yoshikawa N.

Effectiveness of combination therapy in severe childhood IgA nephropathy: long-term results of a randomized, controlled trial.
Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N.

Genotype-phenotype correlation of Japanese X-linked Alport syndrome.
Hashimura Y, Nozu K, Ishimori S, Otsubo H, Hashimoto S, Kaito H, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M.

Compound heterozygous mutations in COL4A3 or COL4A4 may correlate with a better prognosis in autosomal-recessive Alport syndrome.
Oka M, Iijima K, Hashimura Y, Otsuka Y, Kaito H, Nakanishi K, Yoshikawa N, Nozu K, Matsuo M.

Alport-like”glomerular basement membrane changes in a Japanese girl with renal-coloboma syndrome due to *PAX2* mutation.
Otsubo H, Hashimoto S, Ishimori S, Hashimura Y, Fu XJ, Kaito H, Morisada N, Nagatani K, Iijima K, Matsuo M.

Deep intronic mutations in *COL4A5* causes X-linked Alport syndrome.
Hashimoto F, Nozu K, Otsubo H, Ishimori S, Hashimura Y, Kaito H, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M.

Renal biopsy criteria in children with asymptomatic constant isolated proteinuria.
Hama T, Nakanishi K, Mukaiyama H, Togawa H, Shima Y, Tanaka R, Hamahira K, Kaito H, Iijima K, Yoshikawa N.

Validation of the Oxford classification of IgA nephropathy in children.
Shima Y, Nakanishi K, Mukaiyama H, Hama T, Togawa H, Kaito H, Hashimura Y, Iijima K, Yoshikawa N.

Clinical characteristics of silent lupus nephritis in children: a single center experience.
Ishimori S, Otsubo H, Hashimoto F, Hashimura Y, Kaito H, Morisada N, Yoshikawa N, Iijima K, Matsuo M.

ERA-EDTA Congress Praha 2011.6.23-26

Clinical distinction between genetically-proven gitelman's and pseudo-gitelman's syndrome.
Ninchoji T, Kaito H, Nozu K, Hashimura Y, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M.

Investigation of molecular background for patients with exercise-indcuced acute renal failure.
Kaito H, Nozu K, Nakanishi K, Hashimura Y, Shima Y, Ninchoji T, Yoshikawa N, Iijima K, Matsuo M.

XV International Congress of Virology Sapporo 2011. 9. 11-16

Shinya K, Makino A, Ginting TE, Tanaka M, Nakaya T, Nakamura S, Abe Y, Yoshida H, Morioka I, Arakawa S, Takeshima Y, Iwata K, Kawaoka Y.
A potential mechanism of arising viral hemagglutinin mutations in pandemic (H1N1) 2009 viruses.

the 43rd Congress of the International Society of Pediatric Oncology Auckland, New Zealand 2011. 10. 26-30

Place of death of pediatric cancer patients in Japan.
Yanai T, Hirase S, Matsunoshita N, Yamamoto N, Ninchoji T, Kubokawa I, Mori T, Hayakawa A, Takeshima T, Iijima K, Matsuo M.

American Society of Nephrology Kidney Week, Philadelphia 2011.11.8~13

Genetic Backgrounds in Patients with Glomerulopathy with Fibronectin Deposits.
Ohtsubo H, Hashimoto F, Ishimori S, Ninchoji T, Fu XueJun, Hashimura Y, Kaito H, Morisada N, Uesugi N, Iijima K.

Acceleration of Smad3 Phosphorylation at Linker Regions Via c-Jun NH2-terminal Kinase (JNK) in Cyst-Lining Epithelial Cells in cpk Mouse, a Model of ARPKD.
Mukaiyama H, Nakanishi K, Hama T, Togawa H, Shima Y, Miyajima M, Takahashi H, Nagao S, Iijima K, Yoshikawa N.

The American Society of Human Genetics 61th Annual Meeting Montreal 2011.11.11~15

Antisense RNA/Ethylene-bridged nucleic acid chimera induces exon 45 skipping in cultured myocytes from DMD patients with 6 different deletion mutations.
Yagi M, Lee T, Awano H, Takeshima Y, Matsuo M.